Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Update

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 146,700 shares, a decline of 14.1% from the February 13th total of 170,700 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average daily volume of 346,000 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI raised its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the period. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent SEC filing. 10.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Sensei Biotherapeutics in a research note on Wednesday, January 8th.

Sensei Biotherapeutics Trading Up 2.3 %

NASDAQ SNSE opened at $0.45 on Thursday. The stock has a fifty day simple moving average of $0.48 and a 200-day simple moving average of $0.50. The stock has a market cap of $11.32 million, a PE ratio of -0.38 and a beta of 0.16. Sensei Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.94.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.